{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih23xyd4ldmgvvhfkngncizgbcpbh4lcxzrwtc7z5ztssdfuujbie",
    "uri": "at://did:plc:ox2kiwcr2xmn32p25g472pp7/app.bsky.feed.post/3mnmxg7ph2re2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreieej3ovzdm6plqqgn673aylmxxcxipt4y2qnnl63hgzvwp2ugnmbi"
    },
    "mimeType": "image/webp",
    "size": 56334
  },
  "path": "/releases/2026/06/260605023417.htm",
  "publishedAt": "2026-06-05T11:13:02.000Z",
  "site": "https://www.sciencedaily.com",
  "textContent": "Scientists have identified genetic variants that may make some people less responsive to GLP-1 drugs used to treat Type 2 diabetes. Roughly 10% of the population carries these variants, which appear to cause a mysterious form of \"GLP-1 resistance.\" In several clinical trials, carriers were significantly less likely to reach healthy blood sugar targets while taking GLP-1 medications.",
  "title": "Scientists discover why ozempic may not work for some people"
}